All In Biotech

Drug Trial Radar · NCT02474355

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)

Last checked: Nov 20, 2026Latest source record: Nov 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,017

Actual

Start

Sep 18, 2015

Primary completion

Apr 18, 2019

Study completion Apr 18, 2019

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jun 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.

Conditions

  • Lung Cancer

Interventions

  • T790M+ TestingProcedure

    If a previous lab report is unavailable, the patient will need to have T790M+ testing.

  • Baseline Visit Blood & Urine TestingProcedure

    Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria

  • Baseline ECGProcedure

    ECG to ensure absence of any cardiac abnormality

  • Visual Slit-Lamp TestingProcedure

    Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms

  • AZD9291 DosingDrug

    Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From the date of first dose of Osimertinib until the date of death (due to any cause) or last participant contact [up to 43 months]
  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From screening to progression follow-up [every 6 weeks +/- 1 week] relative to the date of enrolment until the end of study [up to 43 months]

Locations

201 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Bedford Park, Australia

  • Research Site

    East Melbourne, Australia

  • Research Site

    Kurralta Park, Australia

  • Research Site

    Randwick, Australia

  • Research Site

    Waratah, Australia

  • Research Site

    Innsbruck, Austria

  • Research Site

    Linz, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Charleroi, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Barretos, Brazil

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Florianópolis, Brazil

  • Research Site

    Ijuí, Brazil

  • Research Site

    Itajaí, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Regina, Saskatchewan, Canada

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Burnaby, British Columbia, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Hamilton, Ontario, Canada

  • Research Site

    North York, Ontario, Canada

  • Research Site

    Oshawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

Showing 40 of 201 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.